---
search:
  boost: 3
---

# Narcolepsy

This is a subcategory of Central Nervous System (CNS) Agents.

## Decision Trees

- [CNS - Narcolepsy - Sunosi, Wakix, Xyrem](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQU5UQUpSTExZNDVYNFJRRElJR1NTMzExWSQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [CNS - Narcolepsy - Xywav](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNEo1WlROV0JLVFE1S0pUTTQ1UDdOSTBVMCQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                                            | Generic Name                                                | Quantity | Time (Days) |
|:-----------------------------------------------------|:------------------------------------------------------------|:--------:|:-----------:|
| Amphetamine / Dextroamphetamine IR, ER <sup>AR</sup> |                                                             |          |             |
| Armodafinil                                          |                                                             |          |             |
| Dextroamphetamine ER <sup>AR</sup>                   | Dextroamphetamine Sulfate ER Cap (all strengths excl 15 MG) |    34    |     34      |
| Dextroamphetamine ER <sup>AR</sup>                   | Dextroamphetamine Sulfate ER Cap 15 MG                      |   136    |     34      |
| Methylphenidate ER <sup>AR</sup>                     |                                                             |          |             |
| Methylphenidate Tab <sup>AR</sup>                    | Methylphenidate HCI Tab (all strengths)                     |   102    |     34      |
| Modafinil                                            |                                                             |          |             |

### Non-Preferred

| Non-Preferred                             | Generic Name | Quantity | Time (Days) |
|:------------------------------------------|:-------------|:--------:|:-----------:|
| Sunosi                                    |              |          |             |
| Wakix                                     |              |          |             |
| Xyrem <sup>BvG ==(Process by NDC)==</sup> |              |          |             |
| Xywav                                     |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least with at least ^^two preferred^^ drugs - either (1) at least ^^30 days^^ modafinil or armodafinil; or (2) at least ^^7 days^^ of a preferred methylphenidate or amphetamine drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Oxybate Salts (Xywav)

Additional Oxybate Salts (Xywav) Criteria

- Must have documented adherence to sodium restricted diet

[**Xyrem Vs Xywav additional criteria information](https://special-spoon-f542dccd.pages.github.io/Pharmacist%20Reference%20Guide/Medication%20Guidance/Xyrem%20vs%20Xywav/)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**AR** - Adderall IR; a PA is required for patients younger than 3 years </br>
**AR** - Adderall XR, Dexedrine ER: a PA is required for patients younger than 6 years </br>
**AR** - Methylphenidate: a PA is required for patients younger than 6 years

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7B73347C85-1D40-4514-80E9-9628185B51B4%7D&file=Denial%20Language%20Updated%2001012024.docx&action=embedview&mobiledirect=true&wdStartOn=37){:target="_blank" rel="noopener"} 

[Criteria](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20criteria%20effective%2001.01.2024.pdf#page=44){ :target="_blank" rel="noopener"} 

[Preferred Drug List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20effective%2001.01.2024.pdf#page=17){ :target="_blank" rel="noopener"} 

[Quantity Limit List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/Quantity%20Limits.pdf){ :target="_blank" rel="noopener"}
